

Friday, 15 September 2017 - Radebeul, Germany & Lyon, France, September 15, 2017 --

RIBOXX PHARMACEUTICALS, a  
biotech  
company  
developing  
Toll-like-receptor  
(TLR) and RIG-I-  
like

-  
Receptor  
(RLR) ligands, and ACCINOV, a  
pharmaceutical  
establishment for  
experimental  
drug  
products

,  
today  
announced  
the  
successful  
industrial  
GMP  
manufacturing

,  
including  
packaging and  
quality  
control of RIBOXXIM®, a  
novel  
and  
highly  
potent  
Toll-like

Receptor  
3 (TLR  
3)-  
ligand.

Manufacturing has been performed with the patented process TENPORA® of RIBOXX in full compliance with the EU GMP requirements, and with the GMP specifications of the experimental drug.

RIBOXXIM® is a proprietary drug substance of RIBOXX PHARMACEUTICALS. It activates the innate immune system to eliminate cancer cells as a validated approach in immuno-oncology with the historical TLR3 ligand poly(I):

C) and  
its  
derivatives

RIBOXXIM® has been validated in multiple pre-clinical studies for immunotherap  
y of cancer. It  
displays unique physico-  
chemical  
and  
biological  
properties  
, as  
well  
as optimal  
biodisponibility  
with  
increased  
stability  
to  
degradation  
in body  
fluids  
such  
as  
human  
plasma. RIBOXXIM®  
is  
stable as a  
drug  
product  
in  
liquid  
form  
for  
several  
months

Prof. Dr. Jacques Rohayem, CEO and CSO of RIBOXX PHARMACEUTICALS de  
clared

:

"  
We  
are  
proud  
to have  
reached  
this  
important  
milestone  
in the  
development  
of TLR3 ligands,  
with  
a unique,  
highly  
potent  
and stable  
drug  
product  
as a  
better  
alternative to poly(I:C) and  
its  
derivatives  
. RIBOXXIM®  
is  
available  
for  
pharmaceuticals  
companies  
or  
universities

developing  
clinical  
applications in  
immuno-onco  
logy  
and  
therapeutic  
vaccines."

André Dupont, President of ACCINOV declared: "We are proud to be the  
manufacturer of  
this  
innovative  
experimental  
drug  
. This  
achievement  
demonstrates  
the high  
flexibility  
of the ACCINOV model."